MorphoSys AG buy Sargnagel
Summary
This prediction ended on 30.09.15 with a price of €60.01. During the runtime of the prediction for MorphoSys AG the price only changed by -0.83%. Sargnagel has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 5.306% | 5.306% | 218.490% | 2.907% |
| iShares Core DAX® | -0.051% | 4.829% | 17.062% | 18.811% |
| iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% | 56.555% |
| iShares Nikkei 225® | 0.658% | -2.173% | 13.159% | 7.768% |
| iShares S&P 500 | 0.964% | 2.547% | 30.492% | 47.355% |
Comments by Sargnagel for this prediction
In the thread Morphosys AG diskutieren
gewagt, aber.....
auch eine große Chance. Die Nachrichten der letzten Tage waren nicht gut. Grundsätzlich handelt es sich bei Morphosys um eine heiße "Kiste". Somit ist alles drin, von einer Kursverdopplung bis zu einem Totalverlust. Eine kleinere Position im Depot ist meines Erachtens - bei den derzeitigen Kursen - jedoch durchaus zu vertreten. INSTINKT PUR - also Vorsicht !